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Background. The relevance of antibodies (Abs) in the defense against Mycobacterium tuberculosis infection remains uncertain.
We investigated the role of Abs to the mycobacterial capsular polysaccharide arabinomannan (AM) and its oligosaccharide (OS)
fragments in humans.
Methods. Sera obtained from 29 healthy adults before and after primary or secondary bacillus Calmette-Guerin (BCG) vacci-
nation were assessed for Ab responses to AM via enzyme-linked immunosorbent assays, and to AM OS epitopes via novel glycan
microarrays. Effects of prevaccination and postvaccination sera on BCG phagocytosis and intracellular survival were assessed in
human macrophages.
Results. Immunoglobulin G (IgG) responses to AM increased signiﬁcantly 4–8 weeks after vaccination (P < .01), and sera were
able to opsonize BCG and M. tuberculosis grown in both the absence and the presence of detergent. Phagocytosis and intracellular
growth inhibition were signiﬁcantly enhanced when BCG was opsonized with postvaccination sera (P < .01), and these enhance-
ments correlated signiﬁcantly with IgG titers to AM (P < .05), particularly with reactivity to 3 AM OS epitopes (P < .05). Further-
more, increased phagolysosomal fusion was observed with postvaccination sera.
Conclusions. Our results provide further evidence for a role of Ab-mediated immunity to tuberculosis and suggest that IgG to
AM, especially to some of its OS epitopes, could contribute to the defense against mycobacterial infection in humans.
Keywords. tuberculosis; Mycobacterium tuberculosis; Mycobacterium bovis BCG; immunoglobulin; human antibodies;
antibody-mediated immunity; immune response; polysaccharide; oligosaccharide; bacterial capsule.
Active tuberculosis remains a major public health problem, with
around 9 million new cases and 1.5 million associated deaths
globally [1]. The only licensed vaccine, bacillus Calmette-Guerin
(BCG), confers limited protection against pulmonary tubercu-
losis, and does not prevent Mycobacterium tuberculosis infec-
tion [2]. Tuberculosis vaccines under development aim to
enhance cell-mediated immunity but, as of today, have not
demonstrated sufﬁcient protective efﬁcacy in humans [2].
Thus, further exploration of other arms of the immune system
may inform new vaccine development strategies.
Increasing evidence suggests that antibodies (Abs) could con-
tribute to the defense against M. tuberculosis [3, 4]. However,
their role is insufﬁciently studied because of the general per-
ception that M. tuberculosis, a largely intracellular pathogen,
is outside the reach of extracellularly located Abs. Abs against
capsular and noncapsular surface polysaccharides are protective
against a variety of microbial pathogens, including those with
intracellular location [4, 5].Mycobacteria have a capsule, an im-
portant virulence factor, that consists largely of polysaccharides,
proteins, and, to a smaller extent, glycolipids [6, 7]. α-glucan
and arabinomannan (AM) account for 70%–80% and 10%–
20% of the polysaccharide content, respectively [8, 9]. We, as
well as others, have previously shown that AM is more immu-
nogenic than α-glucan in patients with tuberculosis [10, 11].We
have further demonstrated that Ab responses to capsular AM
and the related cell wall glycolipid lipoarabinomannan (LAM)
correlate strongly and signiﬁcantly in patients with tuberculosis
[10], suggesting, in accordance with other studies [12], that AM
is the immunogenic portion of LAM. Of note, LAM is not a
component of the mycobacterial capsule [8, 9]. Importantly,
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we and others have shown that passive administration of mono-
clonal Abs (mAbs) to AM and the AM portion of LAM improve
the outcome of M. tuberculosis infection in mice [12, 13] and
that AM-containing conjugate vaccines result in high immuno-
globulin G (IgG) titers to AM and protection of mice against
M. tuberculosis infection (unpublished data) [14, 15]. In hu-
mans, an increase in LAM-speciﬁc Abs after BCG vaccination
has been associated with enhanced innate and cell-mediated
immune responses against BCG [16]. Furthermore, a lack of Abs
to LAM was associated with tuberculosis dissemination in chil-
dren [17]. These experimental and clinical data support the
notion that Abs to AM might play a protective role against
M. tuberculosis infection in both animal models and humans.
In this study, we tested Ab responses to capsular AM in sera
obtained before and after BCG vaccination from adult subjects
undergoing a clinical study to assess mycobacterial growth in-
hibition assays (MGIAs) as correlates for vaccine efﬁcacy [18].
We hypothesized that BCG vaccination would lead to increased
Ab titers to capsular AM, particularly to some of its oligosac-
charide (OS) epitopes, and that such Ab responses would be as-
sociated with defensive effects against mycobacterial infection.
MATERIALS AND METHODS
Subjects
Sera were obtained from 30 healthy,M. tuberculosis–uninfected
adults before and after (weeks 4, 8, and 24) primary or second-
ary BCG vaccination at the University of Oxford (Oxford, Unit-
ed Kingdom) [18]. Participants were recruited under a protocol
approved by the Oxfordshire Research Ethics Committee [18],
and peripheral blood mononuclear cells (PBMCs) from inde-
pendent healthy BCG vaccinated subjects were collected
under a protocol approved by the Institutional Review Board
of the Albert Einstein College of Medicine. Written informed
consent was obtained from all individuals prior to enrollment.
Enzyme-Linked Immunosorbent Assays (ELISAs)
Capsular AM from BCG (Pasteur) or M. tuberculosis (H37Rv)
was isolated, puriﬁed, and lyophilized as described [19]. LAM,
isolated from the cell wall of M. tuberculosis H37Rv, was ob-
tained from BEI Resources (NR-14848). Maxisorp plates were
coated with AM or LAM at 10 μg/mL, sera were added at
1:50 dilution, and ELISAs were performed as described else-
where [10], with further details in the Supplementary Methods.
AM Microarrays
A panel of 12 AM fragments (corresponding to motifs at the
nonreducing terminus of the molecule, which have previously
been shown to be recognized by anti-AM/LAM Abs) [20–22]
were synthesized, coupled to bovine serum albumin via a squa-
rate linker [23], and printed on epoxy-coated glass slides [24].
After blocking, the slides were incubated with sera (1:100), the
murine mAb CS35 (a positive control known to recognize AM
and LAM from various mycobacterial strains [15]),or the murine
IgG2a mAb 9d8 (known to recognize only M. tuberculosis AM)
[13, 15, 19] and processed essentially as reported elsewhere [24],
with details described in the Supplementary Methods. We note
that we used IgG2a 9d8, a switch variant of the protective IgG3
mAb 9d8, which binds to M. tuberculosis AM in a similar man-
ner as the parent mAb [19], for technical reasons, because it does
not clump like the IgG3 isotype and is easier to purify.
Phagocytosis Assay
BCG bacteria were grown in Middlebrook 7H9 and conjugated
with ﬂuorescein isothiocyanate (FITC). Human monocytic cells
(THP-1) were differentiated into adherent macrophages and
then incubated for 2 hours with heat-inactivated sera (10% in
Roswell Park Memorial Institute 1640 medium). The FITC-
labeled BCG was then added at a multiplicity of infection (MOI)
of 20. Phagocytosis was evaluated by ﬂow cytometry, and ﬂuo-
rescence from the noninternalized FITC-labeled BCG was
quenched by treating the cells with trypan blue [25]. We coin-
cubated macrophages and sera prior to BCG infection to allow
simultaneous processing of many samples, which we considered
important for data comparison. To ensure that our method was
comparable to the standard approach, we performed experi-
ments with BCG preopsonized with sera from 3 subjects. To
study any potential additive effects of complement on phagocy-
tosis, sera from 2 subjects were either not heat inactivated or
were supplemented with 1% non–heat-inactivated serum from
a healthy volunteer. We further obtained primary macrophages
from PBMCs of 2 BCG-vaccinated and M. tuberculosis–
uninfected donors as described previously [26], coincubated
those with paired sera from 2 representative subjects, and infect-
ed them with FITC-BCG at MOI of 10. Further details are
described in the Supplementary Methods.
Mycobacterial Growth Assay
THP-1 cells coincubated with paired sera and infected with
BCG at MOI of 10 were harvested, lysed, and plated on days
1 and 4. Colony-forming units were counted after incubation
at 37°C for 3 and 4 weeks. Further details are described in the
Supplementary Methods. Ab responses were further correlated
to PBMC-based MGIAs performed at Oxford University be-
cause whole-blood assays, owing to variability in mycobacterial
stocks and week-to-week performances of the assays, showed
considerably more variation than PBMC-based assays, which
were run in only 2 batches [18].
Transmission Electron Microscopy (TEM) and Immunoﬂuorescence
BCG (Pasteur) or M. tuberculosis (H37Rv) was grown in the
presence and absence of 0.05% tyloxapol. For TEM studies,
BCG strains were ﬁxed as described previously [7]. For immu-
noﬂuorescence studies, ﬁxed BCG or M. tuberculosis was incu-
bated with the murine mAbs IgG1 24C5 to glucan [27], IgG3
CS35 to AM/LAM [15], isotype-matched controls, or human
sera (1:100). Secondary Abs and further details are described
in the Supplementary Methods.
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Assessment of Phagosome-Lysosome (P-L) Fusion
THP-1macrophages were coincubated with 10% heat-inactivated
paired sera from 2 subjects (chosen on the basis of high intra-
cellular growth inhibition rates with postvaccination sera) and
infected with Alexa 488–conjugated BCG [28] at a MOI of 20
for 1 hour, followed by incubation with 100 nM LysoTracker
Red DND-99 (Life Technologies) for 1 hour as described else-
where [29]. After washing and ﬁxing, the cells were examined
with a Leica SP5 confocal microscope, 14–18 images were
taken for each sample, and a minimum of 50 BCG phagosomes
were counted to quantify the percentage of phagosomes co-
localizing with the LysoTracker. Further details are described
in the Supplementary Methods.
Statistical Analysis
Statistical analysis was performed using Prism software, version
6.04 (GraphPad). Comparisons were made using the nonpara-
metric Wilcoxon matched-pairs signed rank test or the Mann–
Whitney U test. Correlations were assessed by Spearman rank
correlation. Correlations involving Ab responses to the 12 AM
epitopes were adjusted for multiple comparisons, using the
Holm-Bonferroni method [30].
RESULTS
Ab Responses Before and After BCG Receipt
In both vaccination groups, compared with sera obtained before
vaccination, sera obtained 4 and 8 weeks after vaccination had
signiﬁcantly higher IgG titers to AM (P < .01), which declined
at 24 weeks (Figure 1A and 1B). Similar increases were observed
for IgG2 responses (Supplementary Figure 1A and 1B), with
a weak correlation between total IgG and IgG2 responses
(r = 0.36, P = .05). While no signiﬁcant differences were observed
between the primary and secondary vaccination groups’ total IgG
responses before and 4 weeks after vaccination (Figure 1C), the
secondary BCG vaccination group had signiﬁcantly higher IgG2
titers at both time points (Supplementary Figure 1C), although
the overall magnitude of IgG2 increase was similar between the
groups. Increases in IgA and IgM titers to AM were only signiﬁ-
cant after secondary vaccination (Supplementary Figures 2 and
3). Of note, 1 subject (in the secondary vaccination group)
with a prevaccination IgG reactivity of 4.9 SDs greater than the
average was excluded as an outlier, while another subject (prima-
ry vaccination group) with a prevaccination value of 1.8 SDs
above average was included, because we used an inclusion thresh-
old of 2 SDs from the mean prevaccination value.
Because knowledge about the similarity in AM and LAM epi-
tope recognition might have important implications, we tested
IgG reactivities to AM isolated from the capsule of both BCG
and M. tuberculosis H37Rv and correlated those to LAM isolated
from the cell wall ofM. tuberculosisH37Rv in postvaccination sera
from 18 randomly chosen subjects (Supplementary Figure 4). The
responses to LAM and AM correlated strongly (P < .0001), with
correlations between LAM and AM isolated from the same strain
(H37Rv) slightly stronger (r = 0.95) than those between AM and
AM or LAM isolated from different strains (r = 0.88).
Ab Responses to AM OS Epitopes
Regardless of vaccination group, subjects’ sera reacted with AM
epitopes in heterogeneous patterns (Figure 2). Overall, second-
ary vaccination appeared to induce more-pronounced IgG re-
sponses to AM OS epitopes than did primary vaccination
(Supplementary Figure 5).
Enhanced BCG Macrophage Phagocytosis With Postvaccination Sera
For both vaccination groups, the THP-1 BCG phagocytosis in-
creased signiﬁcantly upon coincubation with sera obtained 4
and 8 weeks after vaccination (P < .01) but declined with sera
obtained 24 weeks after vaccination (Figure 3A and 3B). Similar
proportional enhancements of BCG phagocytosis were ob-
served when comparing the standard method of preopsonizing
BCG to our method of coincubating macrophages with sera be-
fore BCG infection (Supplementary Figure 6) and when using
Figure 1. Immunoglobulin G (IgG) antibody (Ab) responses to arabinomannan (AM) before and after bacillus Calmette-Guerin (BCG) vaccination. A and B, IgG responses after
primary vaccination (A) and after secondary BCG vaccination (B). The Wilcoxon matched-pairs signed rank test was used for analysis. C, Comparison of IgG responses between
primary and secondary vaccination group, using the Mann–Whitney U test. Circles represent the primary vaccination group, and the squares represent the secondary vacci-
nation group. Lines and error bars represent medians with interquartile ranges. *P < .05, **P < .01, ***P < .001, and ****P < .0001. Abbreviation: NS, not significant (P≥ .05).
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PBMC-derived macrophages (Supplementary Figure 7). How-
ever, with the addition of complement we found no consider-
able differences in phagocytosis between prevaccination and
postvaccination sera (Supplementary Figure 8).
Correlations Between BCG Phagocytosis and IgG Responses to AM and
AM OS Epitopes
Increases in IgG reactivity to native AM by sera obtained 4
weeks after vaccination correlated signiﬁcantly with increases
in BCG phagocytosis when incubating THP-1 cells with the
corresponding sera (P < .01; Figure 3C). The enhanced phago-
cytosis was strongly associated with increased IgG reactivity to
certain AMOS epitopes, namely fragments 3, 6, and 12 (P < .05;
Figure 4A and 4B). Interestingly, all 3 AM OS contained at least
2 residues of mannose (Figure 4C), and 2 of 3 epitopes (frag-
ments 6 and 12) were also recognized by the murine IgG2a
mAb 9d8 to M. tuberculosis AM (Figure 4D) [13, 19]. Of
Figure 2. Immunoglobulin G (IgG) reactivity with a 12-member arabinomannan (AM) oligosaccharide (OS) microarray. Representative microarray images of sera obtained from
3 subjects in the primary (A) and secondary (B) vaccination groups before and 4 weeks after bacillus Calmette-Guerin (BCG) vaccination, demonstrating the heterogeneous
patterns of reactivity to AM OS epitopes (printed in triplicates). For each subject, the brightness and contrast of the images were adjusted with the same settings, using
GenePixPro6.1.
Figure 3. Effects of postvaccination sera on bacillus Calmette-Guerin (BCG) phagocytosis by human macrophages. Phagocytosis rates increased significantly upon coincubation
of THP-1 cells with sera obtained 4 and 8 weeks after vaccination, compared with sera obtained before vaccination, but decreased to prevaccination levels upon coincubation with
sera obtained 24 weeks after vaccination in both the primary (A) and secondary (B) vaccination groups. Lines and error bars represent medians with interquartile ranges. The
Wilcoxon matched-pairs signed rank test was used for analysis. *P < .05, **P < .01, ***P < .001, and ****P < .0001. Of note, 2 subjects, one from the primary vaccination group
and one from the secondary vaccination group, had insufficient serum volume 24 weeks after vaccination and thus have no phagocytosis data for this time point. C, Significant
correlation between immunoglobulin G (IgG) responses to arabinomannan (AM) 4 weeks after vaccination and enhanced BCG phagocytosis (in fold change compared to coin-
cubation with prevaccination sera) by THP-1 cells coincubated with corresponding sera obtained 4 weeks after vaccination, using Spearman rank correlation test. Circles represent
the primary vaccination group, and squares represent the secondary vaccination group. Abbreviations: FITC, fluorescein isothiocyanate; NS, not significant (P≥ .05).
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note, several other segments not associated with phagocytosis
also contained mannose (Supplementary Figure 9).
Effects of Postvaccination Sera on Intracellular Mycobacterial Growth
Reduction
Signiﬁcantly lower BCG growth rates were seen in THP-1 cells
treated with postvaccination sera as compared to prevaccination
sera (P < .01; Figure 5A–E). Moreover, BCG growth reduction cor-
related signiﬁcantly with postvaccination IgG titers to AM (P < .05;
Figure 5F). Because the number of paired sera tested was limited to
10 for practical reasons, correlations of IgG reactivities to AM OS
epitopes lacked statistical power and were thus nonsigniﬁcant.
Ab responses were further correlated to PBMC-basedMGIAs,
for which data were available for 17 subjects, 8 from the primary
and 9 from the secondary vaccination group [18]. At 4 weeks
after vaccination, mycobacterial growth inhibition showed a sig-
niﬁcant correlation with IgG responses to AM (P < .01; Supple-
mentary Figure 10).
TEM and Immunoﬂuorescence Studies
Consistent with other studies, the capsule was partially stripped
off the bacteria when detergent was added to the culture
medium [27, 31], and a thinner but still visible zone was ob-
served surrounding the detergent treated bacteria (Figure 6A).
Figure 4. Enhancement of bacillus Calmette-Guerin (BCG) phagocytosis correlated with arabinomannan (AM)–epitope specific immunoglobulin G (IgG) responses. A, Heat
map showing enhanced phagocytosis associated with antibody (Ab) responses to certain AM epitopes. The heat map was generated using the software MultiExperiment
Viewer (available at: http://www.tm4.org/mev.html). The color feature represents fold change of median fluorescence intensity (MFI; from ≤1 to ≥6) with sera obtained 4
weeks after vaccination, compared with prevaccination sera. The subjects lined from left to right showed enhancement of BCG phagocytosis by THP-1 cells when coincubated
with sera obtained 4 weeks after vaccination, compared with prevaccination sera (from low to high). Primary vaccination subjects’ identifiers are listed in red, and those for
subjects in the secondary vaccination group are in black fonts. B, Significant correlations between increased IgG reactivity to certain AM epitopes 4 weeks after vaccination
and enhanced BCG phagocytosis by human macrophages coincubated with corresponding sera. Analysis was performed by the Spearman rank correlation test and the Holm-
Bonferroni correction for multiple comparisons. C, Structures of AM epitopes 3, 6, and 12. Of note, all 3 segments contained at least 2 residues of mannose (green circles).
Symbols used are those developed by the Consortium for Functional Glycomics, with green circles denoting D-mannose and green stars denoting D-arabinose. D, AM oligo-
saccharide fragments (printed in triplicates) recognized by switch-variant IgG2a of the protective IgG3 monoclonal Ab (mAb) 9d8 against Mycobacterium tuberculosis AM.
Positions of fragments on the microarray are shown below.
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Immunoﬂuorescence microscopy showed that mAbs to α-
glucan and AM/LAM bound to both BCG grown with and
BCG grown without detergent, while an irrelevant isotype-
matched control mAb did not (Figure 6B and 6C). Importantly,
opsonization of BCG andM. tuberculosis grown under both cul-
ture conditions was considerably stronger with postvaccina-
tion serum as compared to prevaccination serum (Figure 6 D
and 6E ).
P-L Fusion
To determine Ab effects on P-L fusion, we assessed paired sera
from 2 representative subjects and found that postvaccination
sera as compared to prevaccination sera enhanced P-L fusion
(Figure 7).
DISCUSSION
Our studies show that primary and secondary BCG vaccination
in humans elicit serum IgG responses to the mycobacterial
capsular polysaccharide AM that correlate strongly and signiﬁ-
cantly with responses to the cell wall glycolipid LAM. In accor-
dance with prior studies investigating Ab reactivities to LAM
[16], we demonstrate enhanced BCG opsonophagocytosis
with postvaccination sera and show that the increased IgG
Figure 5. Bacillus Calmette-Guerin (BCG) growth in human macrophages incubated with postvaccination sera compared to prevaccination sera. THP-1 cells incubated with
heat-inactivated sera obtained before and 8 weeks after vaccination from 10 subjects were infected with BCG (multiplicity of infection, 10) on day 1 and harvested for colony-
forming unit (CFU) counting on days 1 (3 hours after infection) and 4. Of note, sera obtained 8 weeks after vaccination were used because insufficient quantity was left of sera
obtained 4 weeks after vaccination. The 10 subjects were selected on the basis of the highest increase of BCG phagocytosis with THP-1 cells incubated with postvaccination
sera relative to those incubated with prevaccination sera. A–D, Representative BCG growth in THP-1 cells incubated with paired sera (subjects H119 and H124 are from the
primary vaccination group, and subjects H110 and H123 are from the secondary vaccination group). E, Significant BCG growth reduction in THP-1 cells incubated with post-
vaccination sera as compared to prevaccination sera. Because the initial amount of internalized BCG was different between most paired prevaccination and postvaccination sera,
the growth rate was assessed by the proportion of increased bacteria relative to day 1 and was calculated as [CFU at day 4 – CFU at day 1]/CFU at day 1. Comparisons were made
using the Wilcoxon matched-pairs signed rank test. The n value was limited to the top 10 phagocytosis-enhancing sera to allow for the processing of all sera in 1 experiment,
which was performed at 2 separate time points. F, Correlation between immunoglobulin G (IgG) titers 8 weeks after vaccination and mycobacterial growth reduction, using the
Spearman rank correlation test. Circles represent the primary vaccination group, and squares represent the secondary vaccination group. Abbreviation: AM, arabinomannan.
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reactivities to AM are signiﬁcantly associated with enhanced
BCG phagocytosis and growth reduction by human macro-
phages when incubated with the corresponding sera. Our data
suggest that these associations might be driven by IgG responses
targeting 3 speciﬁc AM epitopes. Interestingly, 2 of these epi-
topes are also strongly recognized by the murine mAb 9d8,
which targets M. tuberculosis AM. These results are important
in view of our previous results demonstrating that mAb 9d8
(IgG3) was protective against M. tuberculosis infection in mice
[13], and contribute further supportive evidence for a role of
Ab-mediated immunity in tuberculosis.
AM and LAM are major components of the mycobacterial cell
envelope, and both have critical roles in tuberculosis pathogenesis
[32].Using a variety of AM-binding murine mAbs, data from our
prior studies suggest that human and murine Abs against AM are
diverse and heterogeneous [33].We now provide additional data,
showing that sera from M. tuberculosis uninfected adults recog-
nize AM OS epitopes in heterogeneous patterns before and after
Figure 6. Transmission electron microscopy and immunofluorescence studies of mycobacteria grown without and with detergent. A, A visible electron-transparent zone is
surrounding bacillus Calmette-Guerin (BCG) grown without detergent but not with detergent, indicating reduced capsule formation in the presence of detergent. The scale bar
denotes 100 nm. B–D, Immunofluorescence microscopy of BCG incubated with control monoclonal antibody (mAb) 2D10 (immunoglobulin G1 [IgG1] against the Cryptococcus
neoformans capsular polysaccharide glucuronoxylomannan) and anti-glucan IgG1 mAb 24C5 (B), with control mAb (IgG3, clone B10 of unknown specificity) and anti-LAM IgG3
mAb CS35 (C), and with prevaccination and postvaccination sera from subject H119 (D). E, Immunofluorescence microscopy of Mycobacterium tuberculosis (H37Rv) incubated
with prevaccination and postvaccination sera from subject H119. Paired sera from this subject were selected on the basis of a high postvaccination IgG titer to arabinomannan,
combined with enhanced postvaccination phagocytosis. In each panel of A–D, and in each sub panel of E, the brightness and contrast of the images were adjusted with the
same settings, using ImageJ 1.48. Abbreviation: M. tuberculosis, Mycobacterium tuberculosis.
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primary or secondary BCG vaccination. These results suggest
that individual prior exposure to environmental mycobacteria
and BCG vaccination, and possibly also genetic inﬂuences on im-
mune responses [34], could inﬂuence the repertoire of AM epi-
topes recognized. They further indicate the importance of using
well-deﬁned, homogenous glycans in preference to heteroge-
neous polysaccharides isolated from nature in observational,
mechanistic, and vaccination studies.
The low IgG levels to AM prior to BCG vaccination in both
primary and secondary vaccination groups, as well as their de-
cline to near prevaccination levels at 24 weeks in both vaccination
groups, are consistent with the often less robust and short-lived
Ab responses to carbohydrate antigens and the need for conju-
gate vaccines to elicit lasting Abs [35]. Subjects in the revaccina-
tion group had signiﬁcantly higher IgG2 titers before and after
secondary BCG vaccination than subjects in the primary vaccina-
tion group but overall similar magnitudes in IgG2 responses.
These results indicate that prior BCG vaccination could lead to
ultimately higher titers of IgG2 to AM. The relevance of this ﬁnd-
ing remains to be explored because there is little evidence that
BCG revaccination confers additional protection against tubercu-
losis [36, 37]. The weak correlation between total IgG and IgG2
responses to AM suggests that other IgG subclass responses
against AM are also elicited, consistent with our prior human
data [10], and the observation that IgG subclass responses to car-
bohydrates are not restricted to IgG2 [38].Although not the focus
of this study, we note that the induction of mucosal in addition to
systemic AM-speciﬁc Abs could have important implications for
vaccine efﬁcacy. It is, consequently, noteworthy that oral BCG
vaccination was shown to induce LAM-reactive secretory IgA
[39].We found a broad range of increases in AM-speciﬁc Ab ti-
ters after BCG vaccination, which, along with the epitope-speciﬁc
heterogeneity, is in line with the frequently observed individual
variation of Ab responses to mycobacterial antigens [40].Wheth-
er the heterogeneity in Ab titers and epitope-speciﬁc responses,
and/or the rapid decline of vaccine induced Abs, could be asso-
ciated with the limitations of BCG vaccine effectiveness warrants
further exploration.
The signiﬁcant correlation between the postvaccination AM-
speciﬁc IgG titer and the enhanced BCG phagocytosis and my-
cobacterial growth reduction in macrophages when coincubated
with the corresponding sera suggest that these associations are
FcγR mediated. These results are consistent with data from de
Valliere et al, who demonstrated that Abs to LAM induced by
BCG vaccination were associated with enhanced mycobacter-
ial internalization and growth inhibition by primary human
Figure 7. Effect of postvaccination sera on phagosome-lysosome (P-L) fusion in bacillus Calmette-Guerin (BCG)–infected THP-1 cells. A, THP-1 cells coincubated with sera
obtained from 2 subjects (H123 and H125) before and 4 weeks after vaccination, followed by infection with Alexa 488–conjugated BCG at a multiplicity of infection of 20, were
labeled with LysoTracker probes and analyzed by confocal microscopy. Images show BCG (green) localized within phagosomes, lysosomes (red), and colocalization of BCG/
phagosomes and lysosomes (yellow) indicating P-L fusion. B, The percentage of LysoTracker + BCG/phagosomes (yellow) was considerably higher with postvaccination sera,
relative to that with prevaccination sera, suggesting that the increased antibody reactivity to arabinomannan could reduce intracellular mycobacterial growth via FcɣR-mediated
increase in P-L fusion.
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macrophages and neutrophils [16]. The increase in P-L fusion in
macrophages infected with BCG preopsonized with postvaccina-
tion sera supports that our observed enhanced effects are FcɣR
mediated. These data are in accordance with other studies,
such as that by Armstrong et al, who demonstrated that rabbit
tuberculosis-immune sera opsonizeM. tuberculosis and promote
macrophage phagocytosis, as well as P-L fusion [41]; that by
Kang et al, who showed that entry of ManLAM beads into mac-
rophages via mannose receptors inhibited P-L fusion while entry
of anti-LAM mAb coated beads via FcɣRs did not [42]; and that
by Kumar et al, who recently demonstrated that human natural
opsonizing Abs promote phagosome maturation and restrict M.
tuberculosis survival in human macrophages [43].
We anticipated that some of our observed Ab-associated effects
would have been further increased in the presence of complement
because human IgG can enhance complement activation and in-
crease phagocytosis of BCG and M. tuberculosis by macrophages
[44, 45]. Interestingly, in the presence of complement, phagocyto-
sis was similarly and considerably enhanced with both prevaccina-
tion and postvaccination sera. Prior studies have shown enhanced
phagocytosis via complement receptors with nonimmune sera
[44, 46], but to our knowledge this has not been associated with
reduced intracellular growth or enhanced P-L fusion. Further
studies to elucidate the effects of combined activation of comple-
ment and FcɣRs on intracellularM. tuberculosis survival are need-
ed but were beyond the scope of this study. We also made the
interesting observation that PBMC MGIA results 4 weeks after
vaccination [18] correlated signiﬁcantly with the IgG titers to
AM in the corresponding sera. A possible explanation could be
that the PBMCs may have been coated with AM-speciﬁc Abs,
leading to better uptake and killing of mycobacteria by phagocytic
cells, although the portion of such Abs would almost certainly be
small. Another possibility is that BCG induces both cell-mediated
and humoral immunity.
Glycan microarrays, a recently developed technology [24, 47],
have enabled the identiﬁcation of Abs that recognize immuno-
logically relevant OS fragments from organisms such as Salmo-
nella and malaria parasites [47, 48]. Here, the use of novel
mycobacterial glycan microarrays has enabled us to delineate
the spectrum of Ab responses elicited to AMOS fragments. Our
data suggest that Abs targeting speciﬁc AM OS epitopes could
be more protective than Abs targeting other AM epitopes—a
hypothesis supported by the observation that 2 of 3 epitopes
recognized by human sera overlap with those recognized by
the switch variant of the murine protective mAb 9d8 [13, 19].
Further characterization of human Abs recognizing speciﬁc
AM OSs and the generation of mAbs against these epitopes
are now warranted, to elucidate the speciﬁc mechanisms of such
Abs in vitro and in vivo.
In accordance with other experimental studies, we cultured
BCG in medium supplemented with detergent to avoid heavy
bacterial clumping—an approach required for the feasibility
of our experiments, with the downside of removing the myco-
bacterial capsule to a considerable extent [27, 31].We attempted
to investigate whether subjects’ Abs targeted AM of any poten-
tially remaining capsular fraction or the related motifs present
in cell wall–associated LAM [32]. Consistent with other EM
studies, we saw a clear reduction of the capsule from BCG
grown with detergent as compared to without detergent [31].
Nevertheless, BCG grown under both conditions was reactive
with a mAb directed against capsular α-glucan [9, 27], suggest-
ing that some components of the capsule remained. This ob-
servation was consistent with our prior data showing that the
anti-glucan mAb binds to M. tuberculosis strains grown under
both conditions with only slightly greater apparent afﬁnity for
M. tuberculosis grown without detergent [27]. Thus, the sub-
jects’ Abs could have bound to capsular AM and/or the cell
wall–associated AM portion of LAM, which is supported by
the observation that IgG responses to capsular AM and cell
wall LAM correlated strongly and signiﬁcantly. Of note, when
isolated from the same strain, correlations between reactivities
to AM and LAM were even stronger than correlations between
AM isolated from different strains, supporting that the surface
expression of AM is strain dependent [19, 49, 50]. We further
showed that postvaccination but not prevaccination sera were
reactive with BCG and with M. tuberculosis grown in both the
presence and absence of detergent, conﬁrming that Abs elicited
through BCG vaccination can opsonize both strains, regardless
of culture conditions.
In summary, our studies show that BCG vaccination induces
Abs to the mycobacterial capsular polysaccharide AM in hu-
mans and that these are strongly correlated with reactivities to
the cell wall glycolipid LAM. In accordance with prior studies,
we show that these Ab responses are associated with defense
mechanisms against mycobacterial infection and provide further
evidence indicating that they are FcɣR mediated. Importantly,
this work is the ﬁrst to demonstrate that such Ab responses dis-
play a heterogeneous recognition pattern of speciﬁc AM OS epi-
topes. Our results demonstrate that these Abs are biologically
active in that they can promote mycobacterial opsonization,
phagocytosis, and intracellular growth reduction, and enhance
P-L fusion. Our data support and complement previous experi-
mental and clinical studies demonstrating the relevance of Abs
targeting AM, speciﬁcally some of its OS epitopes, and highlight
the importance of further mechanistic studies with mAbs against
speciﬁc AM glycan structures.
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Supplementary materials are available at http://jid.oxfordjournals.org.
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